Bazinet, A., Ravandi, F., Daver, N., Short, N., Ohanian, M., Yilmaz, M., Sasaki, K., Jabbour, E., Chien, K., DiNardo, C., Haddad, F., Hammond, D., Ishizawa, J., Jain, N., Maiti, A., Masarova, L., Wierda, W., Garcia-Manero, G., Kantarjian, H., Kadia, T. (2025). A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia. Blood. https://doi.org/10.1182/blood-2025-5228